Chemotherapy is another treatment option for bile duct cancer. Chemotherapy works by killing cancer cells in the bile duct. It can be administered as a shot or taken by mouth. Another treatment option for bile duct cancer is immunotherapy. The drugs Ivosidenib and Truseltiq block the FGFR2 protein in cancer cells. This can prevent the cancer from spreading. These drugs are effective in treating advanced stages of the disease.
Some people develop bile duct cancer due to some lifestyle or genetic risk factors. Liver fluke infection, a rare liver disorder, and alcohol use are among the most common causes of bile duct cancer. The infection is caused by parasites called liver flukes, which can invade the bile duct. Other risk factors include pancreatic disease, hepatitis, and alcohol consumption. Additionally, a person may be more likely to develop bile duct cancer if he or she is exposed to certain chemicals. People who work in the automotive or rubber industries may have dioxin exposure.
There are several treatments for bile duct cancer. Surgery is one option for unresectable bile duct cancer. Surgery involves inserting a catheter into the hepatic artery. Unfortunately, the procedure is not for everyone. Some people with bile duct cancer do not have enough health to undergo this surgery. For instance, in February 2022, the U.S. Centers for Disease Control and Prevention (CDC) reported that around 8,000 people in the U.S. are diagnosed with bile duct cancer every year.
As per report published by Coherent Market Insights, global bile duct cancer market is estimated to be valued at US$ 185.4 million in 2021 and is expected to exhibit a CAGR of 12.8% over the forecast period (2021-2028).
One of the new drugs in the treatment of bile duct cancer is known as pemigatinib, also known as Pemazyre. It is an oral kinase inhibitor that has recently been approved by the National Institute of Health and Care Excellence (NICE). According to NICE, this drug will be available to around 50 people who have bile duct cancer.
Immunotherapy is another treatment option. These drugs target the abnormal FGFR2 protein in bile duct cancer cells. By disrupting the blood supply to cancer cells, they can prevent the cancer from growing. Some people with bile duct cancer also have certain other conditions that increase their risk.